
PinkDx, an early-stage women’s health diagnostics company, has secured an additional $5 million in its Series A financing from new investors Blue Venture Fund, Sandbox Clinical Ventures, and BEVC. The extension brings the round’s total to $45 million, following earlier investments from Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital, and Mayo Clinic.
The Daly City-based company is developing diagnostic solutions for women presenting with potential gynecological cancers. Their first test aims to improve diagnostic outcomes for the estimated 1.5 million women in the U.S. who annually present with symptoms like bloating, pelvic pain, and abnormal bleeding that could indicate gynecological cancer.
“We are making great progress in the discovery and development of our first test and this additional funding will help accelerate that process through the test’s clinical validation,” said Bonnie Anderson, PinkDx’s cofounder, chairwoman and chief executive officer.
“Women’s medical needs have been vastly under-served to date,” said Risa Stack, Ph.D., founding partner of BEVC and PinkDx board member. “We believe PinkDx is going to fundamentally change this with its comprehensive approach to applying advanced technology to specific unmet needs and through its team’s proven ability to bring clinically meaningful tests to market.”
The company aims to develop solutions that could replace invasive diagnostic procedures and reduce delays in obtaining answers for the over 100,000 women diagnosed with gynecological cancer annually in the U.S.